Chugai Seiyaku Kabushiki Kaisha

Toru Esaki

Takashi Emura

Eiichi Hoshino

Yoshikazu Nishimura

Naoki Okamoto

Hidetomo Kitamura

Atsuhiko Kato

Yoshiaki Isshiki

Yoshiyuki Furuta

Masateru Ohta

Akemi Mizutani

Tomoya Kotake

Wayne Wen Lai

Tatsuya Tamura

Toshihiko Makino

Kunihiro Hattori

Toshiaki Nagafuji

Toshiro Kozono

Tomokazu Ozaki

Shinya Fujiwara

The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R, R, R, R, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

Spiroimidazolone derivative

The present invention provides compounds represented by formula (1) below and pharmacologically acceptable salts thereof: wherein R, R, R, and Rare as defined in the claims.

Hydantoin derivative

The compounds of the invention are compounds represented by the following general formula (1):wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, Rrepresents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, Rrepresents one selected from the group consisting of a hydrogen atom and alkyl groups, Wrepresents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, Xrepresents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1;and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

Compounds exhibiting thrombopoietin-like activities

Chondrogenesis promoters and indolin-2-one derivatives

Chondrongenesis promotors and indolin-2-one derivatives

Compounds represented by the general formula (1):

Aromatic amine derivatives having NOS inhibiting action

Indolin-2-one derivatives

A compound represented by formula (I): wherein R.sub.1 represents a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a trifluoromethyl group, a lower alkylthio group, an acyl group, a carboxyl group, a mercapto group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an alkoxy group, an acyl group, an aryl group or a heterocyclic group; R.sub.3 represents a lower alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; R.sub.4 represents a hydrogen atom, a lower alkyl group, an aryl group, a heterocyclic group, --OR.sub.5, --SR.sub.5 or --NR.sub.6 R.sub.7 (wherein R.sub.5, R.sub.6, and R.sub.7 each represent a lower alkyl group, etc.); X and Y each represent --CH.sub.2 --, --NH-- or --O--; and n represents an integer of from 0 to 4, and an intermediate for synthesis thereof are disclosed. The compound of the present invention exhibits selective antagonism against gastrin receptors without causing side effects attributed to CCK-A receptor antagonism and is useful for the treatment and prevention of peptic ulcers, gastritis, reflux esophagitis, and Zollinger-Ellison syndrome, and for the treatment of neoplasm originating in the gastrointestinal system.

A compound represented by formula (I): ##STR1## wherein R.sub.1 represents a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a trifluoromethyl group, a lower alkylthio group, an acyl group, a carboxyl group, a mercapto group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an alkoxy group, an acyl group, an aryl group or a heterocyclic group; R.sub.3 represents a lower alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; R.sub.4 represents a hydrogen atom, a lower alkyl group, an aryl group, a heterocyclic group, --OR.sub.5, --SR.sub.5 or --NR.sub.6 R.sub.7 (wherein R.sub.5, R.sub.6, and R.sub.7 each represent a lower alkyl group, etc.); X and Y each represent --CH.sub.2 --, --NH-- or --O--; and n represents an integer of from 0 to 4, and an intermediate for synthesis thereof are disclosed. The compound of the present invention exhibits selective antagonism against gastrin receptors without causing side effects attributed to CCK-A receptor antagonism and is useful for the treatment and prevention of peptic ulcers, gastritis, reflux esophagitis, and Zollinger-Ellison syndrome, and for the treatment of neoplasm originating in the gastrointestinal system.

Growing community of inventors

Shizuoka, Japan

Toru Esaki